Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
Marker Therapeutics, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | -$0.50 | -$0.50 | -$0.50 |
| Q2 2025 | 1 | -$0.55 | -$0.55 | -$0.55 |
| Q3 2025 | 1 | -$0.73 | -$0.73 | -$0.73 |
| Q4 2025 | 1 | -$1.06 | -$1.06 | -$1.06 |
| Q1 2026 | 1 | -$0.20 | -$0.20 | -$0.20 |
| Q2 2026 | 1 | -$0.19 | -$0.19 | -$0.19 |
| Q3 2026 | 1 | -$0.19 | -$0.19 | -$0.19 |
| Q4 2026 | 1 | -$0.19 | -$0.19 | -$0.19 |
Marker Therapeutics, Inc. Earnings Date And Information
Marker Therapeutics, Inc. last posted its earnings results on Monday, March 24th, 2025. The company reported $-1194995.62831 earnings per share for the quarter, missing analysts' consensus estimates of $-0.22 by $1194995.40831. The company had revenue of 6,591.08 B for the quarter and had revenue of 6,591.08 B for the year. Marker Therapeutics, Inc. has generated $-1 earnings per share over the last year ($-1.19 diluted earnings per share) and currently has a price-to-earnings ratio of -0. Marker Therapeutics, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 13th, 2025 based on prior year's report dates.
Marker Therapeutics, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 03/31/2025 | Q4 2024 | N/A | -$0.43 | N/A | $1.22 M | $6,591.08 B |
| 11/14/2024 | Q3 2024 | -$0.39 | -$0.26 | 0.13 | $1.00 M | $1.93 M |
| 08/14/2024 | Q2 2024 | -$0.43 | -$0.25 | 0.18 | $1.17 M | $1.17 M |
| 05/15/2024 | Q1 2024 | -$0.25 | -$0.27 | -0.02 | N/A | $1.24 M |
| 03/25/2024 | Q4 2023 | -$1.00 | -$0.31 | 0.69 | N/A | $1.06 M |
| 11/09/2023 | Q3 2023 | -$0.90 | -$0.34 | 0.56 | N/A | $257,606 |
| 08/14/2023 | Q2 2023 | -$0.80 | -$0.71 | 0.09 | N/A | $762,658 |
| 05/15/2023 | Q1 2023 | N/A | -$0.56 | N/A | N/A | $3.50 M |
| 03/22/2023 | Q4 2022 | -$1.00 | -$0.48 | 0.52 | N/A | $6.05 M |
| 11/10/2022 | Q3 2022 | -$1.30 | -$0.83 | 0.47 | $400,000 | $2.95 M |
| 08/11/2022 | Q2 2022 | -$1.30 | -$1.10 | 0.2 | $2.50 M | $791,000 |
| 05/12/2022 | Q1 2022 | -$1.30 | -$1.19 | 0.11 | $1.00 M | $964,000 |
| 03/17/2022 | Q4 2021 | -$1.20 | -$1.19 | 0.01 | N/A | $1.24 M |
| 11/10/2021 | Q3 2021 | -$1.30 | -$1.50 | -0.2 | N/A | $0 |
| 08/10/2021 | Q2 2021 | -$1.20 | -$1.31 | -0.11 | N/A | $0 |
| 05/12/2021 | Q1 2021 | -$1.60 | -$1.55 | 0.05 | N/A | $0 |
| 03/09/2021 | Q4 2020 | -$1.60 | -$1.75 | -0.15 | N/A | $215 |
| 11/09/2020 | Q3 2020 | -$1.50 | -$1.57 | -0.07 | N/A | $0 |
| 08/10/2020 | Q2 2020 | -$1.40 | -$1.36 | 0.04 | N/A | $466,785 |
| 05/11/2020 | Q1 2020 | -$1.30 | -$1.41 | -0.11 | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Marker Therapeutics, Inc. Earnings: FAQ's
Marker Therapeutics, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Tuesday, May 13th, 2025 based offlast year's report dates.
The conference call for Marker Therapeutics, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Marker Therapeutics, Inc.'s latest earnings report can be read online.
Marker Therapeutics, Inc. (:MRKR) has a recorded annual revenue of $6,591.08 B.
Marker Therapeutics, Inc. (:MRKR) has a recorded net income of $-10,731,315.Marker Therapeutics, Inc. has generated $-1.19 earnings per share over the last four quarters.
Marker Therapeutics, Inc. (:MRKR) has a price-to-earnings ratio of -0 and price/earnings-to-growth ratio is 0.